MK

Manas Kumar Mondal

Director Partner DIN 09261846
DIN 09261846 First appointment Feb 2018 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Feb 2018
Shareholding value •••• Premium profile

About Manas Kumar Mondal

Data last updated:

Manas Kumar Mondal was a Partner at Unus Diagnostics & Medicines Llp (2018–2025) and Director at Canfinis Therapeutics Private Limited (2021–2023). The companies operate in Healthcare.

DIN 09261846
Primary Designation Partner
Industry Healthcare
First Appointment 26 Feb 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Partner26 Feb 20182018₹2.73 Cr (FY 2023)Active
Director30 Jul 20212021₹23.7 Lakh (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Unus Diagnostics & Medicines Llp
Canfinis Therapeutics Private Limited
Premium access

Shareholding and investment profile for Manas Kumar Mondal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manas Kumar Mondal

Manas Kumar Mondal was first appointed on 26 Feb 2018 as Partner at Unus Diagnostics & Medicines Llp. The most recent appointment on record is 30 Jul 2021 at Canfinis Therapeutics Private Limited.

Manas Kumar Mondal held 2 earlier board appointments: Unus Diagnostics & Medicines Llp (Partner, 26 Feb 2018 to 03 Dec 2025); Canfinis Therapeutics Private Limited (Director, 30 Jul 2021 to 20 Sep 2023).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available